Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. - Wikidata - wikimedia - TriplyDB

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

http://www.wikidata.org/entity/Q46142687

about

Extending healthy life span--from yeast to humans SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10.Neuroprotective and disease-modifying effects of the ketogenic diet Role of Sirtuins in Linking Metabolic Syndrome with Depression Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline Protective effects and mechanisms of sirtuins in the nervous system Metabolomics of human brain aging and age-related neurodegenerative diseases Dietary restriction in Drosophila: delayed aging or experimental artefact?Role of the hypothalamus in mediating protective effects of dietary restriction during aging 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease Cilostazol Modulates Autophagic Degradation of β-Amyloid Peptide via SIRT1-Coupled LKB1/AMPKα Signaling in Neuronal Cells SIRT1 and SIRT5 activity expression and behavioral responses to calorie restriction Energy intake and exercise as determinants of brain health and vulnerability to injury and disease Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model.Therapeutic potential of resveratrol in Alzheimer's disease Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.Comparative analysis of microarray data identifies common responses to caloric restriction among mouse tissues Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease.Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle.The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.Caloric restriction impedes age-related decline of mitochondrial function and neuronal activity Gene-environment interaction research and transgenic mouse models of Alzheimer's disease.SIRT1 regulates dendritic development in hippocampal neurons.A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.Does chronic glycolysis accelerate aging? Could this explain how dietary restriction works?Involvement of oxidative stress in Alzheimer disease.Sirtuin1: a promising serum protein marker for early detection of Alzheimer's disease.Intermittent fasting improves functional recovery after rat thoracic contusion spinal cord injury.Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice Dietary restriction delays aging, but not neuronal dysfunction, in Drosophila models of Alzheimer's disease.In vitro caloric restriction induces protective genes and functional rejuvenation in senescent SAMP8 astrocytes.Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging Mitochondrial medicine for aging and neurodegenerative diseases Sirtuins in neurodegenerative diseases: a biological-chemical perspective.

P2860

Q24599191-44D76A17-174D-4DCC-8AE3-BD50C5409C0F Q24601406-232CED06-20F7-4F00-96E4-14A94188CA30 Q24646914-572D0340-001A-4095-85F7-189770BF9290 Q26749937-08510929-890D-4AAD-AADA-28C9C12CE406 Q26784170-D278D44D-25BF-4D25-A7B8-2EDA632459EE Q26825585-A7DD7828-64FF-4774-A18E-A15C220F250C Q26992344-FD1616F5-54F1-4B16-BC7F-7356E42E3F41 Q27314975-5025C45A-67DA-42C3-A8F3-AC1D00789688 Q27692402-3C76F22F-CB9B-487E-BF22-0C6D93B70776 Q28478912-CE44C313-F05F-451E-8805-215A361F2EE0 Q28553396-69B9431D-3AE4-433E-9ECF-02E42372C174 Q28574547-211AA1FE-10D3-425A-B7D2-D65E3FD01E2F Q28710367-46DD96C2-C432-436A-A3F0-04FE52C72B5E Q28752234-F5379F9E-9A3E-4FA4-8F2D-FCE9DFCDE2D1 Q30448973-CED83C23-5BDA-47CF-A20F-1EE95BAFF0C5 Q30499456-1FFCC5FA-3427-4EC0-83F9-0748634A211A Q30538459-E583B3A9-9911-4486-90FA-9B035631ACFA Q30575876-EDFE935C-588E-4DB4-9C58-8D913639407C Q30855117-1B11ED6C-6D84-4E3A-8E5B-6DF1526BA2CE Q31047131-BB295853-30F8-41CD-8DA6-661350974A3B Q31141268-3488025C-B73B-4C7E-B624-A49EAF6EF197 Q33619317-4BA1BD4E-D96A-46A6-B7EB-5E40D7613BE5 Q33751924-9DD5EE58-2108-4C6E-B11F-7EEA1A2DCFBA Q33817811-4D25132F-A26E-4273-BE84-BE4264A30E15 Q33851630-52E156DB-BBB1-4340-B6C0-52BA27F99C72 Q34153460-C405CA45-F9B5-4B81-A9DD-B2D63A2E39C1 Q34189447-CE28B832-4650-421C-848E-E2CCCDE435A0 Q34442806-A2DD0099-3EEF-4FE6-893F-A58F29962F27 Q34493731-BD12CA97-57E7-4EA9-8354-D671FF837EF4 Q34534198-A994FC9F-5DB8-4B72-B4E1-9D771B1C1DD6 Q34542350-504AD66B-2380-4125-A9AC-D28850E9B663 Q34545547-1B866DE4-862E-4CB5-82A4-77A3266EDD14 Q34684563-9F4560DB-4BF4-43A7-8CB1-313BB1E80E2D Q35057728-8CF5453C-0FFE-4701-88AA-D8F3FA769E00 Q35137488-3CC431EC-47CE-4DCC-9129-02F018504B1A Q35223605-57D50B03-C3F1-4768-957D-70C917CBFFCC Q35527157-B6217C4C-600B-4329-8B10-38DE12851157 Q35544420-09116953-63D4-4419-8D1C-D2D673F0FCFF Q35606693-CEA58D86-CC67-4387-B846-375A629AC414 Q35661567-30E0F07A-6A6F-4749-A807-B91AA7925884

P2860

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

http://www.wikidata.org/entity/Q46142687

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@en

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@nl

type

label

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@en

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@nl

prefLabel

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@en

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@nl

P1433

Q46142687-4C059083-B0F7-464F-8314-535DCB07FFB9

P1476

Q46142687-4C0AE60C-03D8-4D09-8959-60E35E9612E5

P2093

Q46142687-0FC07DE2-9002-4330-9488-698D1EB6D52C

Q46142687-57D605DE-6B89-4B2C-B4CB-AA5DB6C01C2C

Q46142687-598BEA3B-D6C1-4A66-B99E-6C49369F157A

Q46142687-7E6A547A-E210-46DB-944D-F0ACBC8823F3

Q46142687-8BE0C3C1-CADF-4D7A-882A-46AF25C073AD

Q46142687-8C3E2AD3-09AD-4051-990D-E60FCDA9D70F

Q46142687-9B1F6EA6-1768-40A8-A430-43C34D97B63E

Q46142687-A13322BB-F16C-43BF-99F6-5FA7F5803B00

Q46142687-F30FC40F-C938-4FC3-AF9B-3A2CFA5260BD

P304

Q46142687-2591B80C-5ADE-41DC-8D7E-4980D8B2D70C

P31

Q46142687-94081129-E24C-4092-984A-7CCB5942FE31

P356

Q46142687-A1E2D040-8DA0-4FCA-856D-54E05F103748

P433

Q46142687-0CD22C02-D63C-4125-9006-ADBE08D042B3

P478

Q46142687-76BB66BC-6C0A-4E72-B906-690DCFD79006

P577

Q46142687-2F1EAEA8-0F68-454B-ACE9-EF13E35D27A2

P698

Q46142687-6499916E-F02B-4E8D-8BA3-AED408C783BE

P921

Q46142687-0629EFB9-61F6-4938-9506-FCD208AD766A

P356

J.NEUROBIOLAGING.2004.09.014

P1433

Neurobiology of Aging

P1476

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.

@en

P2093

Caleb E Finch

http://www.w3.org/2001/XMLSchema#string

David G Morgan

http://www.w3.org/2001/XMLSchema#string

Jerimiah Mason

http://www.w3.org/2001/XMLSchema#string

Karen E Connor

http://www.w3.org/2001/XMLSchema#string

Marcia N Gordon

http://www.w3.org/2001/XMLSchema#string

Nilay V Patel

http://www.w3.org/2001/XMLSchema#string

Robert A Good

http://www.w3.org/2001/XMLSchema#string

Robert W Engelman

http://www.w3.org/2001/XMLSchema#string

Todd E Morgan

http://www.w3.org/2001/XMLSchema#string

P304

995-1000

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROBIOLAGING.2004.09.014

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15748777

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease